Omalizumab facilitates rapid oral desensitization for peanut allergy.

ABSTRACT:

Background

Peanut oral immunotherapy is a promising approach to peanut allergy, but reactions are frequent, and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut updosing and decrease reactions.

Objective

We sought to evaluate whether omalizumab facilitated rapid peanut desensitization in highly allergic patients.

Methods

Thirty-seven subjects were randomized to omalizumab (n = 29) or placebo (n = 8). After 12 weeks of treatment, subjects underwent a rapid 1-day desensitization of up to 250 mg of peanut protein, followed by weekly increases up to 2000 mg. Omalizumab was then discontinued, and subjects continued on 2000 mg of peanut protein. Subjects underwent an open c

SUBMITTER: MacGinnitie AJ 

PROVIDER: S-EPMC5369605 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature